TRITRIAL : The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life
© 2024 Richeldi et al..
Purpose: The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed combination in patients with chronic obstructive pulmonary disease (COPD) in a real-world setting, focusing on patient's experience and perspective through the use of patients reported outcomes.
Patients and Methods: TRITRIAL was a multicenter, prospective, observational study conducted on patients with moderate-severe COPD treated with BDP/FF/G fixed therapy for 12 months. The main objective was to evaluate the impact of BDP/FF/G on health status through the COPD Assessment Test (CAT) score. Additional assessments included adherence and satisfaction, measured by the TAI-10/12 questionnaire and a specifically designed eight-item questionnaire, quality of life through the EQ-5D-5L test, sleep quality through the COPD and Asthma Sleep Impact Scale (CASIS), as well as safety and disease-related outcomes.
Results: Data from 655 patients were analyzed in the study. The mean total CAT score significantly improved (from 22.8 at baseline to 18.1 at 6 months and 16.5 at 12 months; p < 0.0001), as well as all the eight CAT sub-items, which decreased on average by 0.5-0.9 points during the study. Adherence and usability of the inhaler also improved during the study, with a decrease in poor compliance (from 30.1% to 18.3%) and an increase in good compliance (from 51.8% to 58.3%) according to the TAI score. Patients also benefited from significantly improved quality of life (EQ Index from 0.70 to 0.80; EQ-5D VAS score from 55.1 to 63.1) and sleep quality (CASIS score from 41.1 to 31.8). Finally, patients reported a significant reduction in exacerbation during the study.
Conclusion: TRITRIAL showed that the BDP/FF/G fixed combination is effective and safe in patients with moderate-severe COPD and poorly controlled disease, improving patients' HRQoL, sleep quality, adherence and inhaler usability and reducing COPD symptoms and the risk of exacerbation in a real-life setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
International journal of chronic obstructive pulmonary disease - 19(2024) vom: 12., Seite 475-487 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Richeldi, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.2147/COPD.S445858 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36924995X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36924995X | ||
| 003 | DE-627 | ||
| 005 | 20240305232732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/COPD.S445858 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM36924995X | ||
| 035 | |a (NLM)38435125 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Richeldi, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TRITRIAL |b The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Richeldi et al. | ||
| 520 | |a Purpose: The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed combination in patients with chronic obstructive pulmonary disease (COPD) in a real-world setting, focusing on patient's experience and perspective through the use of patients reported outcomes | ||
| 520 | |a Patients and Methods: TRITRIAL was a multicenter, prospective, observational study conducted on patients with moderate-severe COPD treated with BDP/FF/G fixed therapy for 12 months. The main objective was to evaluate the impact of BDP/FF/G on health status through the COPD Assessment Test (CAT) score. Additional assessments included adherence and satisfaction, measured by the TAI-10/12 questionnaire and a specifically designed eight-item questionnaire, quality of life through the EQ-5D-5L test, sleep quality through the COPD and Asthma Sleep Impact Scale (CASIS), as well as safety and disease-related outcomes | ||
| 520 | |a Results: Data from 655 patients were analyzed in the study. The mean total CAT score significantly improved (from 22.8 at baseline to 18.1 at 6 months and 16.5 at 12 months; p < 0.0001), as well as all the eight CAT sub-items, which decreased on average by 0.5-0.9 points during the study. Adherence and usability of the inhaler also improved during the study, with a decrease in poor compliance (from 30.1% to 18.3%) and an increase in good compliance (from 51.8% to 58.3%) according to the TAI score. Patients also benefited from significantly improved quality of life (EQ Index from 0.70 to 0.80; EQ-5D VAS score from 55.1 to 63.1) and sleep quality (CASIS score from 41.1 to 31.8). Finally, patients reported a significant reduction in exacerbation during the study | ||
| 520 | |a Conclusion: TRITRIAL showed that the BDP/FF/G fixed combination is effective and safe in patients with moderate-severe COPD and poorly controlled disease, improving patients' HRQoL, sleep quality, adherence and inhaler usability and reducing COPD symptoms and the risk of exacerbation in a real-life setting | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adherence | |
| 650 | 4 | |a beclometasone/formoterol/glycopyrronium | |
| 650 | 4 | |a chronic obstructive pulmonary disease | |
| 650 | 4 | |a fixed triple therapy | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a real-world | |
| 650 | 7 | |a Beclomethasone |2 NLM | |
| 650 | 7 | |a KGZ1SLC28Z |2 NLM | |
| 650 | 7 | |a Glycopyrrolate |2 NLM | |
| 650 | 7 | |a V92SO9WP2I |2 NLM | |
| 650 | 7 | |a Formoterol Fumarate |2 NLM | |
| 650 | 7 | |a W34SHF8J2K |2 NLM | |
| 650 | 7 | |a Fumarates |2 NLM | |
| 700 | 1 | |a Schino, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Bargagli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ricci, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rocca, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Marchesani, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pennisi, Alfio |e verfasserin |4 aut | |
| 700 | 1 | |a Camiciottoli, Gianna |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amato, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Macagno, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Scaffidi Argentina, Ulrica |e verfasserin |4 aut | |
| 700 | 1 | |a Ingrassia, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Piraino, Alessio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of chronic obstructive pulmonary disease |d 2006 |g 19(2024) vom: 12., Seite 475-487 |w (DE-627)NLM175408165 |x 1178-2005 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g day:12 |g pages:475-487 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/COPD.S445858 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |b 12 |h 475-487 | ||